Moreover, a novel BH3 mimetic named ABT-263 with high affinity for BCL-XL, BCL-2 and BCL-w has been proven to exert both cytotoxic and cytostatic effects on EC cells in vitro and has entered clinical trials for the treatment of cancer. This evidence concerns the gene BCL2L1 and cancer.